Baxter International Inc'

1
Baxter Patient Safety
ADV06/058C
2
Who is Baxter?
Baxter is a global diversified healthcare company
applying innovative science to develop speciality
therapeutics and medical products that save and
sustain patients' lives.
3
Baxter International Inc.
At Baxter, one of our primary goals is to advance
the best in healthcare worldwide. Every day, our
products and services help treat thousands of
people around the world with some of the most
complex conditions from haemophilia to cancer
and immune disorders to kidney disease.
4
Global Company Snapshot

• Seventy-five years of market leadership driven by
  a well-recognized global brand
• 9.8 billion global market leader
• More than 1.5 million invested in RD every day
• Over 50 of sales and earnings outside the United
  States
• Over 47,000 employees around the world in more
  than 250 facilities

5
in the UK
Established in the UK for 45 years, Baxter is
one of the largest suppliers to the NHS,
providing services to almost every hospital in
the UK and supporting patients in the community.
6
A History of Innovation

• The first commercially manufactured intravenous
  (IV) solutions
• The first needleless system for IV therapy
• The first pre-mixed drug solutions
• The first plastic container for IV solutions
• The first commercially built artificial kidney
• The first peritoneal dialysis (PD) solutions and
  delivery systems
• The first commercially produced Factor VIII
  concentrate to treat haemophilia

In 1933, the company opened its first
manufacturing facility in a renovated automobile
showroom in Glenview, Illinois. There, six
employees turned out the complete line of five
solutions in glass containers.
7
Comprehensive Portfolio

• Focus on essential therapies for life-threatening
  conditions
• Leveraging capabilities across businesses to
  provide high quality, cost-effective products and
  services

BioScience Biopharmaceuticals and devices for
chronic conditions, including haemophilia, immune
deficiencies and other blood-related disorders
Medication Delivery Systems to deliver fluids and
medication to patients.
Renal Systems and products used in the treatment
of people with kidney disease
8
Advancing Patient Safety
Baxter supports the NHS in advancing patient
safety by continuously innovating treatments and
the delivery of care for people with critical
conditions.

• Baxters 45-year relationship with the NHS
  ensures that healthcare providers and patients
  can have confidence in our products and services.
• Baxter listens to the concerns of patients and
  professionals about safety in healthcare,
  responding with innovative treatments and
  products that are dependable and easy to use.
• Baxter works with policy makers to develop and
  support patient safety initiatives

9
Advancing Patient Safety

• Baxter was the first manufacturer of commercially
  prepared intravenous solutions, leading the way
  to future developments in flexible, non-PVC,
  closed system IV solutions such as premixed drugs
  that reduce the opportunity for medication error.
  

10
Advancing Patient Safety
Baxter was the first to introduce recombinant
products for haemophilia and the first third
generation FVIII. ADVATE, is the only rFVIII
that does not contain blood components. Products
without blood components virtually eliminate any
potential risk of transmission of human
blood-borne pathogens. ADVATE exceeds
guidelines on pathogen risk reduction to ensure
continued patient safety.
Dan Jolley (left), a student at the University of
Southampton Medical School uses Baxters ADVATE
recombinant Factor VIII to prevent severe
internal bleeding episodes caused by haemophilia.
11
Advancing Patient Safety

• Baxter has built long term partnerships in
  pharmacy compounding at the Christie, Oxford and
  Mount Vernon Hospitals by utilising state of the
  art equipment that produces high quality, ready
  to administer, parenteral cancer therapies.

Mike Richards, NHS National Cancer Director,
visits the Baxter Compounding Unit in Manchester
which compounds cytotoxic drugs for the Christie
Hospital, the largest hospital in Europe dealing
with cancer treatment.
12
Advancing Patient Safety
To further support the Purchasing for Safety
project, Baxter has invested significant funds to
provide clinical, cost effective data and
evidence in areas such as medical device
standardisation and risk reduction in the
preparation of IV therapy.

• Intravenous administration of drugs has been
  identified as the route most commonly involved
  with errors 1
• Studies have shown that IV error rates varied
  between 27-49and the majority of errors were
  likely to be moderate to severe in outcome for
  the patient 2
• Building a Safer NHS identifies IV infusions as
  an area where particular effort needs to be made
  to improve medication safety 3

1 Upton D. Preventing ADEs at the point of care.
Hospital Pharmacy Europe. March/April 2004 2
Wirtz V Taxis K Narber ND. An observational study
of IV medication errors in the UK and Germany
Pharm World Sci 2003 25104-11 3 Building a
safer NHS for patients improving medication
safety Department of Health 20045 5.7.4
13
Purchasing for Safety Project

• APPG for Patient Safety launched by Lord Warner
  Liam Donaldson March 05
• How can safety be incorporated within the NHS to
  add value?
• Businesses like Baxter focus product
  development around innovation for safety
• How can we create a uniform safety agenda?
• Lord Warner invites Baxter to a meeting
• DH, PASA, NPSA and Industry to work to build a
  best practice model for procurement

?
14
Advancing Patient Safety

• Baxter was the first company to develop dedicated
  software and accessories for paediatric Automated
  Peritoneal dialysis, specifically designed to
  reduce the risk of overfill when dialysing
  children as small as 2kgs in weight
• Baxter PD systems advance patient safety
  exceeding the minimum peritonitis rates as
  specified in the Renal Association Standards

HomeChoice, Baxters Automated Peritoneal
dialysis system for paediatrics and adults.
15
What Patient Safety Means To Us
Patient safety is and always has been at the
forefront of everything we do. The NHS is under a
huge amount of pressure, so we are always looking
for an improved safety option. Baxter works in
partnership with healthcare providers and policy
makers to develop and support patient safety
initiatives. Huw
Williams, General Manager Baxter Healthcare Ltd
It is my job to work with policy makers and to
listen to the concerns of patients and
professionals about safety in healthcare, to
ensure Baxter responds with innovative treatments
and products that are dependable and easy to
use. Louise Warwick, Patient Safety
Manager
In addition to supplying products that help
reduce medication errors and increase safety for
patients and healthcare workers, we also provide
professional training, dependable service and
comprehensive back-up support to ensure that
healthcare providers and patients have confidence
to use our products.

Dariusz Szawlowski, Group Product Manager,
Infusion Systems
16
Making a Meaningful Difference